{"nctId":"NCT01764633","briefTitle":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","startDateStruct":{"date":"2013-02-08","type":"ACTUAL"},"conditions":["Dyslipidemia"],"count":27564,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Evolocumab","type":"EXPERIMENTAL","interventionNames":["Biological: Evolocumab"]}],"interventions":[{"name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ≥ 40 to ≤ 85 years of age\n* History of clinically evident cardiovascular disease at high risk for a recurrent event\n* Fasting low-density lipoprotein cholesterol (LDL-C) ≥ 70 mg/dL (≥ 1.8 mmol/L) ) or non-high-density lipoprotein cholesterol (non-HDL-C) ≥ 100 mg/dL (\\> 2.6 mmol/L)\n* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) class III or IV, or last known left ventricular ejection fraction \\< 30%\n* Uncontrolled hypertension\n* Uncontrolled or recurrent ventricular tachycardia\n* Untreated hyperthyroidism or hypothyroidism\n* Homozygous familial hypercholesterolemia\n* LDL or plasma apheresis","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization","description":"All deaths and potential endpoint events were adjudicated by an independent external Clinical Events Committee (CEC) led by the Thrombolysis in Myocardial Infarction (TIMI) Study Group, using standardized definitions based on the \"Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction\".\n\nTime to cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.11","spread":null},{"groupId":"OG001","value":"2.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.01","spread":null},{"groupId":"OG001","value":"5.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.32","spread":null},{"groupId":"OG001","value":"7.25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.66","spread":null},{"groupId":"OG001","value":"9.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.72","spread":null},{"groupId":"OG001","value":"10.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.64","spread":null},{"groupId":"OG001","value":"12.57","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cardiovascular Death, Myocardial Infarction, or Stroke","description":"All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the \"Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction\". Time to cardiovascular death, myocardial infarction, or stroke was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":null},{"groupId":"OG001","value":"1.65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.68","spread":null},{"groupId":"OG001","value":"3.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.18","spread":null},{"groupId":"OG001","value":"4.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.83","spread":null},{"groupId":"OG001","value":"5.47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.31","spread":null},{"groupId":"OG001","value":"6.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.93","spread":null},{"groupId":"OG001","value":"7.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cardiovascular Death","description":"All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the \"Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction\".\n\nCardiovascular death includes death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure (HF), death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes.\n\nTime to cardiovascular death was defined as the time from randomization to the date of cardiovascular death and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on the last confirmed survival status date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":null},{"groupId":"OG001","value":"0.39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.82","spread":null},{"groupId":"OG001","value":"0.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null},{"groupId":"OG001","value":"1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":null},{"groupId":"OG001","value":"1.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null},{"groupId":"OG001","value":"2.11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":null},{"groupId":"OG001","value":"2.49","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to All Cause Death","description":"Time to all-cause death was defined as the time from randomization to the date of death and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on the last confirmed survival status date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":null},{"groupId":"OG001","value":"0.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null},{"groupId":"OG001","value":"1.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.96","spread":null},{"groupId":"OG001","value":"1.94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.78","spread":null},{"groupId":"OG001","value":"2.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":null},{"groupId":"OG001","value":"3.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.28","spread":null},{"groupId":"OG001","value":"4.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Myocardial Infarction","description":"All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the \"Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction\".\n\nThe diagnosis of myocardial infarction required the combination of:\n\n* Evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and\n* Supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery Imaging.\n\nTime to first myocardial infarction was defined as the time from randomization to the date of the first MI and was analyzed using Kaplan-Meier survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":null},{"groupId":"OG001","value":"1.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":null},{"groupId":"OG001","value":"1.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":null},{"groupId":"OG001","value":"2.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.30","spread":null},{"groupId":"OG001","value":"3.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.25","spread":null},{"groupId":"OG001","value":"3.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.28","spread":null},{"groupId":"OG001","value":"4.41","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Stroke","description":"All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the \"Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction\".\n\nStroke was defined as an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction.\n\nTime to first stroke was defined as the time from randomization to the date of the stroke and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":null},{"groupId":"OG001","value":"0.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.30","spread":null},{"groupId":"OG001","value":"1.05","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.80","spread":null},{"groupId":"OG001","value":"1.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null},{"groupId":"OG001","value":"1.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":null},{"groupId":"OG001","value":"2.18","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Coronary Revascularization","description":"All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions based on the \"Standardized Definitions for Cardiovascular and Stroke End Point Events in Clinical Trials and the Third Universal Definition of Myocardial Infarction\".\n\nTime to first coronary revascularization was defined as the time from randomization to the date of the coronary revascularization and was analyzed using Kaplan-Meier (KM) survival analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.87","spread":null},{"groupId":"OG001","value":"1.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.71","spread":null},{"groupId":"OG001","value":"3.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.20","spread":null},{"groupId":"OG001","value":"4.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.57","spread":null},{"groupId":"OG001","value":"5.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.91","spread":null},{"groupId":"OG001","value":"6.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.17","spread":null},{"groupId":"OG001","value":"7.01","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Cardiovascular Death or First Hospitalization for Worsening Heart Failure","description":"All events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions.\n\nHF hospitalization was defined as an event that met all of the following criteria:\n\n1. Admitted to hospital with a primary diagnosis of HF\n2. In hospital for at least 24 hours\n3. Documented new or worsening symptoms due to HF, including at least 1 of the following:\n\n   * Dyspnea\n   * Decreased exercise tolerance\n   * Fatigue\n   * Other symptoms of worsened end-organ perfusion or volume overload\n4. Evidence of new or worsening HF consisting of at least 2 physical exam findings or 1 physical exam finding and at least 1 laboratory criterion\n5. Received new or increased treatment for HF. Time to CV death or first hospitalization for worsening HF was defined as the time from randomization to the first occurrence of any component of the endpoint analyzed using KM survival analysis. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":null},{"groupId":"OG001","value":"1.29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.99","spread":null},{"groupId":"OG001","value":"1.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":null},{"groupId":"OG001","value":"2.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":null},{"groupId":"OG001","value":"3.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":null},{"groupId":"OG001","value":"4.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Ischemic Fatal or Non-Fatal Stroke or Transient Ischemic Attack","description":"All deaths and potential endpoint events were adjudicated by an independent external CEC led by the TIMI Study Group, using standardized definitions.\n\nIschemic stroke was defined as an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction of central nervous system tissue. Transient ischemic attack (TIA) was defined as a transient episode of focal neurological dysfunction caused by brain, spinal cord, or retinal ischemia, without acute infarction.\n\nTime to first ischemic fatal or non-fatal stroke or TIA was defined as the time from randomization to the first occurrence of any component of the composite endpoint and was analyzed using KM analysis. KM estimates of the percentage of participants with an event are reported. Participants with no event were censored based on last non-fatal potential endpoint collection date.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.61","spread":null},{"groupId":"OG001","value":"0.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":null},{"groupId":"OG001","value":"0.83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":null},{"groupId":"OG001","value":"1.18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.05","spread":null},{"groupId":"OG001","value":"1.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.40","spread":null},{"groupId":"OG001","value":"1.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":null},{"groupId":"OG001","value":"2.48","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3404,"n":13756},"commonTop":["Diabetes mellitus","Hypertension","Nasopharyngitis","Upper respiratory tract infection"]}}}